Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,shortTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,EDTXF,-470000.0,243426000,,,-1645000,,-1645000,2247000,605000,-1746000,-1746000,24000,-7000,,,,0,746000,2492000,141000,101000,,-1645000,-1645000,242000.0,7981000.0,8617000.0,-228000.0,671000.0,8389000.0,74005000.0,-91354000.0,5181000.0,9140000.0,5203000.0,2877000.0,9140000.0,1189000.0,6958000.0,720000.0,367000.0,2119000.0,,-194000.0,-117000.0,-28000.0,1410000.0,-279000.0,1438000.0,-604000.0,-52000.0,-1845000.0,80000.0,-19000.0,-460000.0,672000.0,-189000.0,,4081000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,SPECTRAL MEDICAL INC,False,False,PNK,0.2602,1630419775,0.0,0.275,0.2602,0.2602,80000,REGULAR,0,4,0.0,0.2602 - 0.2602,0.2602,0.0,0.0,0,0,finmb_34635,Spectral Medical Inc.,Other OTC,CAD,15060,17933,0.010199994,0.040799975,0.25 - 0.598,-0.3378,-0.56488293,0.25,0.598,1616761800,1616761800,1616761800,-0.025,0.09,-0.02,-13.01,-0.001,0.30422223,-0.044022232,-0.1447042,0.39387682,-0.13367683,-0.3393874,63339444,2.891111,-260.19998,15,America/New_York,EDT,-14400000,1.64,,,0.598,0.25,0.3042,0.3939,15.06k,17.93k,243.43M,,156.02M,19.97%,15.00%,,,,,,,,,,,0.00%,,"Dec 18, 2011",,,"Dec 30, 2020","Mar 30, 2021",0.00%,-295.26%,-42.79%,"-28,698.04%",2.22M,0.01,18.20%,1.47M,-6.32M,-7.32M,-0.0250,,5.2M,0.02,646k,,2.42,-0.00,-7.17M,-4.45M,Value,M9C 1C2,Healthcare,29,"Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",Toronto,416-626-3233,ON,1609372800,Canada,http://www.spectraldx.com,86400,135 The West Mall,Diagnostics & Research,Unit 2
t-1,EDTXF,-915000.0,243426000,,,-2147000,,-2147000,1895000,342000,-1788000,-1788000,154000,-7000,,,,0,535000,2323000,193000,-359000,,-2147000,-2147000,246000.0,7981000.0,8832000.0,-669000.0,676000.0,8163000.0,71870000.0,-89709000.0,5348000.0,9189000.0,5807000.0,2902000.0,9189000.0,1113000.0,6804000.0,260000.0,348000.0,187000.0,232000.0,204000.0,-92000.0,-28000.0,21000.0,23000.0,51000.0,-1769000.0,-155000.0,-1543000.0,81000.0,-5000.0,70000.0,231000.0,-100000.0,-2000.0,3902000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,SPECTRAL MEDICAL INC,False,False,PNK,0.2602,1630419775,0.0,0.275,0.2602,0.2602,80000,REGULAR,0,4,0.0,0.2602 - 0.2602,0.2602,0.0,0.0,0,0,finmb_34635,Spectral Medical Inc.,Other OTC,CAD,15060,17933,0.010199994,0.040799975,0.25 - 0.598,-0.3378,-0.56488293,0.25,0.598,1616761800,1616761800,1616761800,-0.025,0.09,-0.02,-13.01,-0.001,0.30422223,-0.044022232,-0.1447042,0.39387682,-0.13367683,-0.3393874,63339444,2.891111,-260.19998,15,America/New_York,EDT,-14400000,1.64,,,0.598,0.25,0.3042,0.3939,15.06k,17.93k,243.43M,,156.02M,19.97%,15.00%,,,,,,,,,,,0.00%,,"Dec 18, 2011",,,"Dec 30, 2020","Mar 30, 2021",0.00%,-295.26%,-42.79%,"-28,698.04%",2.22M,0.01,18.20%,1.47M,-6.32M,-7.32M,-0.0250,,5.2M,0.02,646k,,2.42,-0.00,-7.17M,-4.45M,Value,M9C 1C2,Healthcare,29,"Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",Toronto,416-626-3233,ON,1609372800,Canada,http://www.spectraldx.com,86400,135 The West Mall,Diagnostics & Research,Unit 2
t-2,EDTXF,1102000.0,243426000,,,-1577000,,-1577000,1595000,299000,-1372000,-1372000,-3000,-8000,,,,0,418000,1790000,119000,-205000,,-1577000,-1577000,250000.0,7981000.0,8649000.0,1352000.0,668000.0,10001000.0,71777000.0,-87562000.0,5515000.0,9156000.0,7576000.0,2529000.0,9156000.0,1090000.0,8661000.0,330000.0,343000.0,788000.0,,-1006000.0,-83000.0,-27000.0,-389000.0,97000.0,51000.0,-2654000.0,-5000.0,-2177000.0,79000.0,5000.0,71000.0,154000.0,-83000.0,-362000.0,6132000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,SPECTRAL MEDICAL INC,False,False,PNK,0.2602,1630419775,0.0,0.275,0.2602,0.2602,80000,REGULAR,0,4,0.0,0.2602 - 0.2602,0.2602,0.0,0.0,0,0,finmb_34635,Spectral Medical Inc.,Other OTC,CAD,15060,17933,0.010199994,0.040799975,0.25 - 0.598,-0.3378,-0.56488293,0.25,0.598,1616761800,1616761800,1616761800,-0.025,0.09,-0.02,-13.01,-0.001,0.30422223,-0.044022232,-0.1447042,0.39387682,-0.13367683,-0.3393874,63339444,2.891111,-260.19998,15,America/New_York,EDT,-14400000,1.64,,,0.598,0.25,0.3042,0.3939,15.06k,17.93k,243.43M,,156.02M,19.97%,15.00%,,,,,,,,,,,0.00%,,"Dec 18, 2011",,,"Dec 30, 2020","Mar 30, 2021",0.00%,-295.26%,-42.79%,"-28,698.04%",2.22M,0.01,18.20%,1.47M,-6.32M,-7.32M,-0.0250,,5.2M,0.02,646k,,2.42,-0.00,-7.17M,-4.45M,Value,M9C 1C2,Healthcare,29,"Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",Toronto,416-626-3233,ON,1609372800,Canada,http://www.spectraldx.com,86400,135 The West Mall,Diagnostics & Research,Unit 2
t-3,EDTXF,2614000.0,243426000,,,-1949000,,-1949000,1901000,338000,-1641000,-1641000,4000,-9000,,,,0,517000,2158000,179000,-308000,,-1949000,-1949000,255000.0,7981000.0,9955000.0,2869000.0,953000.0,12824000.0,71858000.0,-85985000.0,5682000.0,9015000.0,10230000.0,3647000.0,9015000.0,1081000.0,11488000.0,401000.0,348000.0,783000.0,,-755000.0,-118000.0,-27000.0,4651000.0,-138000.0,5100000.0,2459000.0,-471000.0,-1603000.0,74000.0,-86000.0,637000.0,614000.0,-128000.0,-422000.0,7841000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,SPECTRAL MEDICAL INC,False,False,PNK,0.2602,1630419775,0.0,0.275,0.2602,0.2602,80000,REGULAR,0,4,0.0,0.2602 - 0.2602,0.2602,0.0,0.0,0,0,finmb_34635,Spectral Medical Inc.,Other OTC,CAD,15060,17933,0.010199994,0.040799975,0.25 - 0.598,-0.3378,-0.56488293,0.25,0.598,1616761800,1616761800,1616761800,-0.025,0.09,-0.02,-13.01,-0.001,0.30422223,-0.044022232,-0.1447042,0.39387682,-0.13367683,-0.3393874,63339444,2.891111,-260.19998,15,America/New_York,EDT,-14400000,1.64,,,0.598,0.25,0.3042,0.3939,15.06k,17.93k,243.43M,,156.02M,19.97%,15.00%,,,,,,,,,,,0.00%,,"Dec 18, 2011",,,"Dec 30, 2020","Mar 30, 2021",0.00%,-295.26%,-42.79%,"-28,698.04%",2.22M,0.01,18.20%,1.47M,-6.32M,-7.32M,-0.0250,,5.2M,0.02,646k,,2.42,-0.00,-7.17M,-4.45M,Value,M9C 1C2,Healthcare,29,"Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada.",Toronto,416-626-3233,ON,1609372800,Canada,http://www.spectraldx.com,86400,135 The West Mall,Diagnostics & Research,Unit 2
